Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer

NCT01275859 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Letrozole, Lapatinib

Sponsor

Asan Medical Center